Background: Both an elevated homocysteine (Hcy) level and depression are risk factors for cognitive impairment in the general population, but no study has analyzed whether the coexistence of an elevated Hcy level and late-life depression (LLD) is associated with worse cognitive performance.
Objective: We aimed to investigate the relationship between Hcy levels and cognitive function in individuals with LLD and whether the coexistence of an elevated Hcy level and LLD is associated with worse cognitive performance.
Methods: A total of 113 LLD patients and 89 normal controls underwent a standardized clinical interview and comprehensive neuropsychological assessment battery. Plasma concentrations of Hcy were detected. Factorial analyses were performed to examine the impact of the coexistence of an elevated Hcy level and LLD on cognitive performance.
Results: Plasma Hcy levels in patients with LLD were significantly higher than that in normal controls. Only for LLD patients, Hcy level was negatively correlated with global cognition, executive function, attention, and visual space. The factorial analysis showed that there was a significant interactive effect of Hcy level (normal and elevated levels) and LLD (with and without LLD) on global cognition. In post hoc comparisons, the elderly individuals with both elevated Hcy levels and LLD tended to have the worst global cognitive function compared with those with LLD or elevated Hcy levels alone.
Conclusions: The coexistence of an elevated Hcy level and LLD was associated with worse cognitive performance. Early intervention should be initiated to protect cognition in LLD patients with elevated Hcy levels.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jad.2020.08.022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevalence and risk factors of stroke in patients with non-valvular atrial fibrillation: a case-control study.
World Neurosurg
January 2025
Department of Neurology, General Hospital of Ningxia Medical University, Yinchuan, 750000, Ningxia Hui Autonomous Region, China. Electronic address:
Objective: To analyze the prevalence and influencing factors of stroke in patients with non-valvular atrial fibrillation (SIPWNVAF), and to provide a reference basis for the prevention and control of stroke.
Methods: Data were obtained from the China National Stroke Screening Survey (CNSSS). From January 2016 to December 2023, a total of 15471 permanent residents aged ≥ 40 years in Yinchuan were screened.
Development and validation of a novel model to predict post-stroke cognitive impairment within 6 months after acute ischemic stroke.
Front Neurol
December 2024
Department of Neurology, Huai'an First People's Hospital, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, China.
Background: Cognitive decline following acute ischemic stroke (AIS), termed post-stroke cognitive impairment (PSCI), is a prevalent phenomenon that significantly elevates disability and mortality rates among affected patients. The objective of this investigation was to develop a robust clinical prediction model capable of forecasting PSCI within six months post-AIS and subsequently validate its effectiveness.
Methods: A cohort of 573 AIS patients was stratified into two groups: those with PSCI (260 cases) and those who remained cognitively normal (CN) (313 cases).
Association Between Folate Metabolism Risk, Collateral Circulation, and Hemorrhagic Risk in Moyamoya Disease.
Transl Stroke Res
January 2025
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No.119 Nan Si Huan Xi Road, Fengtai District, Beijing, China.
Methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) polymorphisms are known risk factors for vascular diseases due to the impact on folate metabolism dysfunction and homocysteine (Hcy) accumulation. This study aimed to investigate the association between folate metabolism risk and hemorrhagic risk in moyamoya disease (MMD). In this prospective study, we enrolled 350 MMD patients with complete genotype data for MTHFR and MTRR.
View Article and Find Full Text PDFAssociations between paraoxonase-1 activity and therapeutic drug monitoring indicators in schizophrenia patients treated with olanzapine: A cross-sectional study.
J Psychopharmacol
January 2025
Psychiatric Research Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
Objective: Therapeutic drug monitoring (TDM) indicators have been suggested to predict overall outcome responses to olanzapine (OLZ) treatments in terms of efficacy and metabolic syndrome. This study aimed to investigate whether paraoxonase-1 (PON-1) activity can be used to predict schizophrenia patient outcomes.
Methods: Schizophrenic patients ( = 50) aged between 20 and 65 years who received OLZ treatment were recruited, and their Positive and Negative Syndrome Scale scores, PON-1 activity, and olanzapine drug levels normalized by dose (OLZ/D) and its metabolite N-desmethyl-olanzapine (DMO), together with biochemical parameters, were determined.
Analysis of risk factors for abnormal renal function in patients with gout in Southwest China: a cross-sectional study.
Rheumatol Adv Pract
December 2024
Department of Rheumatology and Immunology, Clinical Medical College, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, PR China.
Objective: To analyse the associations between renal function and clinical laboratory indicators and explore the renal function abnormality risk factors for gout patients in Southwest China.
Methods: Outpatient and hospitalized gout patients ( = 4384) at the First Affiliated Hospital of Chengdu Medical College between January 2017 and December 2020 were divided into normal ( = 2393) and abnormal ( = 1991) renal function groups according to their eGFR. The relationships between clinical laboratory indicators and the eGFR were analysed, and a logistic regression model was fit to identify significant risk factors.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!